UK biotechnology company Verona Pharma has appointed an experienced industry leader, Dr Sven Jan-Anders Karlsson, as its new CEO.
Dr Karlsson replaces Verona’s co-founder Michael Walker, who is stepping down as CEO but will remain as a senior scientific advisor.
The new CEO has widespread leadership experience in the life science industry, with roles including director at biotech company S*BIO, executive VP of pharmaceutical global research at Bayer HealthCare, and senior positions at Rhone-Poulenc Rorer and Astra.
Verona’s Chair, Professor Clive Page, commented: “We have taken time to identify and recruit the right person to take over from Michael after he had notified the Board of his intention to step down.
“We believe Jan-Anders’ experience in the pharmaceutical and biotechnology sector will be invaluable to Verona Pharma as we move our clinical programmes forward, and continue to grow and expand the company.”
Based in London, Verona Pharma is a biotechnology company that specialises in developing new medicines for chronic respiratory diseases.
Share this article: